Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Yunfei Lv, Kuang Chen, Chunmei Yang, De Zhou, Juying Wei, Wanzhuo Xie, Gongqiang Wu, Jingcheng Zhang, Qin Pan, Jie Jin, Yanhong Tong, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2025-7253

Published: 2025

Journal Articles

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Blood (2025) 146 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2025-7229

Published: 2025

Journal Articles

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

Xueying Yang, Xin Huang, Jiejing Qian, Xingnong Ye, Gaixiang Xu, Wenjuan Yu, Mixue Xie, Hongyan Tong, De Zhou

Blood (2025) 146 (Supplement 1): 7149.

https://doi.org/10.1182/blood-2025-7149

Published: 2025

Journal Articles

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang, Xingnong Ye, Chunmei Yang, Juying Wei, De Zhou, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2025-3596

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Linjie Li, Beili Hu, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2025-1911

Published: 2025

Journal Articles

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Xiang Zhang, Liping Mao, Xia Li, Xingnong Ye, Mixue Xie, De Zhou, Xiudi Yang, Jian Huang, Wenjuan Yu, Juying Wei, Min Yang, Yinjun Lou, Yanhong Tong, Jie Jin

Blood (2025) 146 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2025-3464

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

A novel random survival forest model for adult NPM1-mutated Acute Myeloid Leukemia patients

Yiyi Yao, Lijie Wang, Xucan Lou, Yile Zhou, Shasha Zhang, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Yanhong Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Ning Zhang, Zhaoxiang Wang, Jie Jin, Huafeng Wang

Blood (2025) 146 (Supplement 1): 6134.

https://doi.org/10.1182/blood-2025-6134

Published: 2025

Journal Articles

Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma

Chunmei Yang, Chao Hu, Juying Wei, Liping Mao, Huafeng Wang, Liangshun You, De Zhou, Haitao Meng, Gaixiang Xu, Liya Ma, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2025-1859

Published: 2025

Journal Articles

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2025-1907

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Blood (2025) 146 (1): 76–88.

https://doi.org/10.1182/blood.2024027689

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood (2025) 145 (14): 1526–1535.

https://doi.org/10.1182/blood.2024026401

Published: 2025

Includes: Supplemental data

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Yafang Ma, Xiang Zhang, Jian Hou, Lijing Shen, Fei Li, Fancong Kong, Ying Lu, Guowei Li, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2024-203359

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

A novel random survival forest model for adult NPM1-mutated Acute Myeloid Leukemia patients

Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only